Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $8.2 million.

  • Revolution Medicines' Other Accumulated Expenses rose 544.84% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 544.84%. This contributed to the annual value of $583,000 for FY2024, which is 85.04% down from last year.
  • Per Revolution Medicines' latest filing, its Other Accumulated Expenses stood at $8.2 million for Q3 2025, which was up 1,683.77% from $462,000 recorded in Q2 2025.
  • Revolution Medicines' Other Accumulated Expenses' 5-year high stood at $8.2 million during Q3 2025, with a 5-year trough of $99,000 in Q2 2021.
  • Its 3-year average for Other Accumulated Expenses is $1.6 million, with a median of $651,000 in 2025.
  • As far as peak fluctuations go, Revolution Medicines' Other Accumulated Expenses slumped by 85.64% in 2021, and later skyrocketed by 671.49% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Other Accumulated Expenses stood at $311,000 in 2021, then surged by 62.38% to $505,000 in 2022, then spiked by 671.49% to $3.9 million in 2023, then crashed by 85.04% to $583,000 in 2024, then skyrocketed by 544.84% to $8.2 million in 2025.
  • Its Other Accumulated Expenses was $8.2 million in Q3 2025, compared to $462,000 in Q2 2025 and $651,000 in Q1 2025.